Want to see JP:4570 full AI Analyst Report?

Immuno-Biological Laboratories Co., Ltd. (4570) Price & Analysis

0 Followers

4570 Stock Chart & Stats

¥1404.00

¥18.00(3.96%)

At close: Jan 08 4:00 PM EST

¥1404.00

¥18.00(3.96%)

Day’s Range― - ―

52-Week Range¥464.00 - ¥3,820.00

Previous CloseN/A

Volume75.00K

Average Volume (3M)23.51K

Market Cap

¥9.93B

Enterprise Value¥8.23K

Total Cash (Recent Filing)¥907.94M

Total Debt (Recent Filing)¥171.81M

Price to Earnings (P/E)26.1

Beta0.90

Next Earnings

Oct 30, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend Yield0.58%

Share Statistics

EPS (TTM)39.54

Shares Outstanding9,314,590

10 Day Avg. Volume28,690

30 Day Avg. Volume23,506

Financial Highlights & Ratios

PEG Ratio1.18

Price to Book (P/B)6.78

Price to Sales (P/S)12.44

P/FCF Ratio46.69

Enterprise Value/Market CapN/A

Enterprise Value/RevenueN/A

Enterprise Value/Gross ProfitN/A

Enterprise Value/EbitdaN/A

Forecast

1Y Price TargetN/A

Price Target UpsideN/A

Rating ConsensusN/A

Number of Analyst Covering0

EPS Forecast (FY)N/A

Revenue Forecast (FY)N/A

Bulls Say, Bears Say

Bulls Say

Strong ProfitabilityThe latest results show a high-margin operating model with strong gross, operating and net profitability. Sustained margins would provide resources for product development and help the company absorb moderate fluctuations in research spending.

Conservative Balance SheetLow leverage and rising equity give the company financial flexibility to fund operations and commercial development without heavy reliance on borrowing. Improved ROE also indicates that the turnaround is producing more efficient use of shareholder capital.

Rebounded Cash GenerationStrong operating and free cash flow in the latest year indicates that reported earnings are converting into liquidity. This supports reinvestment in research reagents, working capital needs and resilience during periods of uneven laboratory demand.

Bears Say

Turnaround Durability RiskThe sharp shift from substantial losses to strong profits demonstrates improvement but also highlights limited proof of stability across cycles. If demand, product mix or execution weakens, earnings could remain more volatile than current margins suggest.

Uneven Cash-Flow HistoryAlthough cash generation recovered strongly in 2026, the prior pattern shows that accounting profits have not consistently translated into cash. Continued volatility could constrain investment capacity and make funding dependent on maintaining the recent recovery.

Moderate Revenue GrowthRevenue growth remains positive but modest relative to the importance of expanding the research-reagent customer base. Without faster adoption, new product contribution or broader market penetration, maintaining current profitability may depend heavily on margins.

4570 FAQ

What was Immuno-Biological Laboratories Co., Ltd.’s price range in the past 12 months?

Immuno-Biological Laboratories Co., Ltd. lowest stock price was ¥464.00 and its highest was ¥3820.00 in the past 12 months.

What is Immuno-Biological Laboratories Co., Ltd.’s market cap?

Immuno-Biological Laboratories Co., Ltd.’s market cap is ¥9.93B.

When is Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date?

Immuno-Biological Laboratories Co., Ltd.’s upcoming earnings report date is Oct 30, 2026 which is in 72 days.

How were Immuno-Biological Laboratories Co., Ltd.’s earnings last quarter?

Immuno-Biological Laboratories Co., Ltd. released its earnings results on Aug 07, 2026. The company reported ¥10.76 earnings per share for the quarter, missing the consensus estimate of N/A by N/A.

Is Immuno-Biological Laboratories Co., Ltd. overvalued?

According to Wall Street analysts Immuno-Biological Laboratories Co., Ltd.’s price is currently Overvalued. Get more investment ideas with TipRanks Premium

Does Immuno-Biological Laboratories Co., Ltd. pay dividends?

Immuno-Biological Laboratories Co., Ltd. pays a Notavailable dividend of ¥7.5 which represents an annual dividend yield of 0.58%. See more information on Immuno-Biological Laboratories Co., Ltd. dividends here

What is Immuno-Biological Laboratories Co., Ltd.’s EPS estimate?

Immuno-Biological Laboratories Co., Ltd.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Immuno-Biological Laboratories Co., Ltd. have?

Immuno-Biological Laboratories Co., Ltd. has 9,314,590 shares outstanding.

What happened to Immuno-Biological Laboratories Co., Ltd.’s price movement after its last earnings report?

Immuno-Biological Laboratories Co., Ltd. reported an EPS of ¥10.76 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.261%.

Which hedge fund is a major shareholder of Immuno-Biological Laboratories Co., Ltd.?

Currently, no hedge funds are holding shares in JP:4570

What is the TipRanks Smart Score and how is it calculated?

Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology

Company Description

Immuno-Biological Laboratories Co., Ltd.

Immuno-Biological Laboratories Co., Ltd. (IBL) is a global entity dedicated to the research, development, production, and distribution of immunological reagents. The company's diverse offerings include ELISA assay kits designed for the precise quantitative measurement of targeted substances, alongside comprehensive research support services focusing on areas such as Alzheimer's disease, metabolic syndrome, and cancer. IBL also caters to specific client needs through customized services for antibody production and the development of bespoke ELISA systems. A prominent service is LipoSEARCH, which provides tailored lipoprotein profiling and analysis utilizing gel-filtration high-performance liquid chromatography. This advanced method allows for the in-depth examination of even minute plasma or serum samples from both humans and small animals, supporting a broad spectrum of research, including lipid metabolism, the creation of pharmaceuticals for lifestyle-related diseases, functional food development, and clinical investigations. For animal health, IBL offers LipoTEST, a diagnostic and health screening tool for veterinary clinics, complemented by personalized biomarker testing services for lifestyle-related conditions. Furthermore, the company operates an innovative protein production division that leverages transgenic silkworms. This technology is instrumental in manufacturing antibodies for research and diagnostic applications, human collagen for cosmetic use, proteins for drug development, and other specialized proteins. Established in 1982, Immuno-Biological Laboratories Co., Ltd. is headquartered in Fujioka, Japan.